Efficacy of Ritlecitinib

Ritlecitinib (Ritlecitinib) is a kinase inhibitor that promotes the reduction of absolute lymphocyte levels, T lymphocytes (CD3) and T lymphocyte subsets (CD4 and CD8) in a dose-dependent manner. Rituxitinib also promoted the reduction of NK cells (CD16/56), which remained stable at week 48 after starting treatment. In patients treated with rituxitinib 50 mg once daily, the decrease in median lymphocyte levels persisted through week 48.5.

At 12 times the mean maximum dose of 50 mg once daily in patients with alopecia areata, ritixitinib had no clinically relevant effect on the QTc interval. Use of ritixitinib has been associated with the development of serious infections, malignancies (including non-melanoma skin cancers), major adverse cardiovascular events, thromboembolic events, and hypersensitivity reactions. In another postmarketing safety study of JAK inhibitors, JAK inhibitors were associated with higher all-cause mortality, including sudden cardiovascular death, compared with tumor necrosis factor blockers.

Adverse reactions greater than or equal to 1% of adverse reactions include headache, diarrhea, acne, rash, urticaria, folliculitis, fever, atopic dermatitis, dizziness, herpes zoster, stomatitis, and common laboratory abnormalities include increased blood creatine phosphokinase (CPK), decreased red blood cell count, decreased platelet count, and elevated liver enzymes. Ritexitinib is a new drug for the treatment of alopecia areata. It has not yet been launched in the country and has not been included in the medical insurance. Its price has not yet been learned. For specific prices and drug details, please consult a medical consultant.